Swiss National Bank
CRVS icon

Swiss National Bank’s Corvus Pharmaceuticals CRVS Stock Holding History

Swiss National Bank’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Buy
+126,500
New +$1.76M ﹤0.01% 1973

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Swiss National Bank's CRVS Position: Q2 2026 in Review

Swiss National Bank opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 126,500 shares worth $1.89M. The stake represents ﹤0.01% of the portfolio and ranks #1973 among its holdings.

174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Swiss National Bank held 126,500 shares of Corvus Pharmaceuticals worth $1.89M as of Q2 2026.
  • Corvus Pharmaceuticals was a new Swiss National Bank position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1973 holding.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.